ANTX
AN2 Therapeutics, Inc.
AN2 Therapeutics (ANTX) Q2 2026 earnings
Published Aug 11, 2026
AI summary
- GAAP EPS −$0.18 beat the −$0.24 consensus by $0.06, up from −$0.21 a year ago.
- AN2 Therapeutics reported a net loss of $8.185 million for the second quarter of 2026.
- The company is advancing three Phase 2 clinical programs across polycythemia vera, M. abscessus, and Chagas disease.
- Research and development expenses rose to $6.019 million due to increased clinical and preclinical trial activity.
- The company ended the quarter with $79.9 million in cash, equivalents, and investments to fund operations into 2029.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.18
Consensus −$0.24
Beat by $0.06GAAP EPS: −$0.18
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company is a clinical-stage firm with no commercial revenue and ongoing net losses.
- Future clinical trial results and enrollment timelines remain subject to uncertainty.
Read original report
Source: AN2 Therapeutics, Inc. press release · SEC Form 8-K exhibit 99.1